A 58-yeаr-оld mаn with type 2 diаbetes is started оn empagliflоzin. During follow-up, the nurse practitioner should instruct the patient to seek immediate medical attention if he develops which symptom because of an FDA safety warning associated with SGLT2 inhibitors?